Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

1. Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

mutation-positive advanced non-small-cell lung cancer (TA653) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 17This guidance replaces TA416. 1 1 Recommendations Recommendations 1.1 Osimertinib is recommended as an option for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non- small-cell lung cancer (NSCLC) in adults, only if: • their disease has progressed (...) Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer Osimertinib for treating EGFR T790M mutation- positive advanced non-small- cell lung cancer T echnology appraisal guidance Published: 14 October 2020 www.nice.org.uk/guidance/ta653 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

2. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer Osimertinib for untreated EGFR mutation-positive non- small-cell lung cancer T echnology appraisal guidance Published: 14 October 2020 www.nice.org.uk/guidance/ta654 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful (...) a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 20Contents Contents 1 Recommendation 4 2 Information about osimertinib 5 Marketing authorisation

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

3. Recommendations for the Management of Actionable Incidental Findings in the Lung Cancer Screening Pilot for People at High Risk

and relevant clinical information will be reported in the Impressions section of the reporting template, and the S-Modifier should be utilized For each IF, follow up recommendations were developed for actionable scenarios and are described in the summary table. References 1. CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. Lynch, David A. et al. 1, Octover 2015, Radiology, Vol. 277. 2. Selection criteria for lung-cancer screening. Tammemägi MC, Katki HA (...) Recommendations for the Management of Actionable Incidental Findings in the Lung Cancer Screening Pilot for People at High Risk 525 University Avenue, 5th Floor, Toronto ON, M5G 2L3 Guidelines for the Management of Actionable Incidental Findings in the Lung Cancer Screening Pilot for People at High Risk Dr. Micheal McInnis, Lead, Radiology Quality Assurance, University Health Network Dr. Heidi Schmidt, Clinical Radiology Lead, Lung Cancer Screening Pilot for People at High Risk Michelle Ang

2020 Cancer Care Ontario

4. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

% in females, respectively [2]. Non-small cell lung cancer (NSCLC) accounts for 80%–90% of lung cancers, while small cell lung cancer (SCLC) has been decreasing in frequency in many countries over the past two decades [4]. During the last 25 years, the distribution of histological types of NSCLC has changed: in the United States, squamous cell carcinoma (SCC), formerly the predominant histotype, decreased, while adenocarcinoma has increased in both genders. In Europe, similar trends have occurred in men (...) , while in women, both SCC and adenocarcinoma are still increasing [5]. The World Health Organization (WHO) estimates that lung cancer is the cause of 1.59 million deaths globally per year, with 71% of them caused by smoking. Tobacco smoking remains the main cause of lung cancer and the geographical and temporal patterns of the disease largely reflect tobacco consumption during the previous decades. Both smoking prevention and smoking cessation can lead to a reduction in a large fraction of lung

2020 European Society for Medical Oncology

5. Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer. (Abstract)

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.In this double-blind, phase 3 trial, we randomly assigned patients with completely resected EGFR mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily (...) ) or placebo for 3 years. The primary end point was disease-free survival among patients with stage II to IIIA disease (according to investigator assessment). The secondary end points included disease-free survival in the overall population of patients with stage IB to IIIA disease, overall survival, and safety.A total of 682 patients underwent randomization (339 to the osimertinib group and 343 to the placebo group). At 24 months, 90% of the patients with stage II to IIIA disease in the osimertinib group

2020 NEJM

6. Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer. (Abstract)

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. Among patients with non-small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET receptor, has shown activity in cancer models with various types of MET activation.We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients with MET-dysregulated advanced NSCLC. Patients were (...) assigned to cohorts on the basis of previous lines of therapy and MET status (MET exon 14 skipping mutation or MET amplification according to gene copy number in tumor tissue). Patients received capmatinib (400-mg tablet) twice daily. The primary end point was overall response (complete or partial response), and the key secondary end point was response duration; both end points were assessed by an independent review committee whose members were unaware of the cohort assignments.A total of 364 patients

2020 NEJM

7. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model. (Abstract)

Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model. Lung cancer screening with chest computed tomography (CT) reduces lung cancer death. Centers for Medicare & Medicaid Services (CMS) eligibility criteria for lung cancer screening with CT require detailed smoking information and miss many incident lung cancers. An automated deep-learning approach based on chest radiograph images may (...) identify more smokers at high risk for lung cancer who could benefit from screening with CT.To develop and validate a convolutional neural network (CXR-LC) that predicts long-term incident lung cancer using data commonly available in the electronic medical record (EMR) (chest radiograph, age, sex, and whether currently smoking).Risk prediction study.U.S. lung cancer screening trials.The CXR-LC model was developed in the PLCO (Prostate, Lung, Colorectal, and Ovarian) Cancer Screening Trial (n = 41 856

2020 Annals of Internal Medicine

8. Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer. (Abstract)

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. RET fusions are oncogenic drivers in 1 to 2% of non-small-cell lung cancers (NSCLCs). In patients with RET fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown.We enrolled patients with advanced RET fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary

2020 NEJM

9. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. (Abstract)

The Effect of Advances in Lung-Cancer Treatment on Population Mortality. Lung cancer is made up of distinct subtypes, including non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Although overall mortality from lung cancer has been declining in the United States, little is known about mortality trends according to cancer subtype at the population level because death certificates do not record subtype information.Using data from Surveillance, Epidemiology, and End Results (...) (SEER) areas, we assessed lung-cancer mortality and linked deaths from lung cancer to incident cases in SEER cancer registries. This allowed us to evaluate population-level mortality trends attributed to specific subtypes (incidence-based mortality). We also evaluated lung-cancer incidence and survival according to cancer subtype, sex, and calendar year. Joinpoint software was used to assess changes in incidence and trends in incidence-based mortality.Mortality from NSCLC decreased even faster than

2020 NEJM

10. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer

in the Cancer Drugs Fund, crizotinib was not a comparator in this appraisal (issue 1, see technical report pages 12 to 14). • The relevant population was the STARTRK-2 subgroup of 78 patients who had: - a confirmed diagnosis of ROS1-positive non-small-cell lung cancer (NSCLC) - measurable disease at baseline - no minimum follow-up restriction - the licensed 600-mg entrectinib dose - no prior ROS1 inhibitor treatment. Analyses based on the STARTRK-2 subgroup were appropriate for decision making (issue 2, see (...) with various gene alterations (n=207) and included 78 people with Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 8 of 16ROS1-positive NSCLC. Most (73%) people had previous therapy for advanced disease and everyone had the licensed entrectinib dose. Data from the STARTRK-2 subgroup (May 2018 enrolment data cut-off) were used

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

11. Lung cancer: NCCP advice for medical professionals on the management of patients undergoing Lung Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) pandemic

Alternative RT schedule/Alternative treatment options Level 5 Less than 10 % capacity Individual case discussion Version: 1 Department: NCCP Radiation Oncology Working Group Update date: 05/06/2020 Code: RO_COVID19_12 3 5 Radical Radiotherapy/SABR (Non-metastatic NSCLC & Limited Stage SCLC) Non-Small Cell Lung Cancer (NSCLC) Stage/clinical scenario Potential selection criteria Treatment recommendations T1-T2 (selected T3), N0, M0 – eligible for SABR Small tumour and slow growing disease (documented slow (...) but eligible for radical radiotherapy Small tumour and slow growing disease (documented slow growth of previous imaging or pure lepidic adenocarcinoma on biopsy & imaging) Delay (taking into account capacity, risk/benefit to patient) or standard T1-T2 (selected T3) N0, M0 – non- eligible for SABR but eligible for radical radiotherapy Large tumour and/or tumour with documented progression on previous serial imaging and/or pathological subtype other than pure lepidic adenocarcinoma Standard Locally advanced

2020 Health Service Executive (Ireland) - Clinical Guidelines

12. Selpercatinib (Retevmo) - lung and thyroid cancers

Selpercatinib (Retevmo) - lung and thyroid cancers Drug Approval Package: RETEVMO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: RETEVMO Company: Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company. Application Number: 213246 Approval Date: 05/08/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2020 FDA - Drug Approval Package

13. Lung Cancer Screening with Low-Dose CT: a Meta-Analysis

Lung Cancer Screening with Low-Dose CT: a Meta-Analysis Lung Cancer Screening with Low-Dose CT: a Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get the latest research from NIH: . Find NCBI SARS-CoV-2 literature (...) management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Review J Gen Intern Med Actions . 2020 Jun 24. doi: 10.1007/s11606-020-05951-7. Online ahead of print. Lung Cancer Screening with Low-Dose CT: a Meta-Analysis , , , Affiliations Expand Affiliations 1 University of Iowa Carver College of Medicine, Iowa City, IA, USA. richard-m-hoffman@uiowa.edu. 2 Holden Comprehensive Cancer

2020 EvidenceUpdates

14. Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

treatment ? any tumour treatment until disease progression and discontinuation of the study medication ? denosumab c Extract of dossier assessment A19-86 Version 1.0 Atezolizumab (small cell lung cancer) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 11 - Table 7: Characteristics of the intervention – RCT, direct comparison: atezolizumab + carboplatin + etoposide versus placebo + carboplatin + etoposide(multipage table) Study Intervention Comparison a. Treatment could (...) of the best supportive care (BSC) during the maintenance phase. Extract of dossier assessment A19-86 Version 1.0 Atezolizumab (small cell lung cancer) 13 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 12 - Treatment was performed until disease progression, unacceptable toxicity, start of another tumour therapy, withdrawal of consent or death; administration of atezolizumab could be continued beyond progression at the investigator’s discretion if clinical benefit continued

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

15. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

2020 EvidenceUpdates

16. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

need and comparator There is an unmet need for treatment options in this disease There is an unmet need for treatment options in this disease 3.1 A patient expert highlighted that people diagnosed with extensive-stage small- cell lung cancer (ES-SCLC) are often dismayed at their lack of treatment options, particularly compared with non-small-cell lung cancer (NSCLC). Treatment options have not changed for decades, and patients are aware of the success of immunotherapy for treating other cancers (...) concluded that the company's time-to-death approach to estimate utilities was acceptable for this particular appraisal, given the specific circumstances, but this should not be considered the usual methodology for this disease. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 17The duration of treatment benefit

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

17. Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)

Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) T echnology appraisal guidance Published: 30 June 2020 www.nice.org.uk/guidance/ta635 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Contents Contents Advice 3 Information 3 Ramucirumab (...) with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 3Advice Advice NICE is unable to make a recommendation about the use in the NHS of ramucirumab with erlotinib for untreated epidermal growth factor receptor (EGFR)-positive metastatic non-small-cell lung cancer because Eli Lilly and Company Limited did

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

18. Lurbinectedin (Zepzelca) - To treat metastatic small cell lung cancer

Lurbinectedin (Zepzelca) - To treat metastatic small cell lung cancer Drug Approval Package: ZEPZELCA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ZEPZELCA Company: Pharma Mar USA, Inc. Application Number: 213702 Approval Date: 06/15/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

19. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy. PMID: 32150489 DOI: Item in Clipboard Full-text links Cite Abstract Purpose: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report (...) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other

2020 EvidenceUpdates

20. Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer

Capmatinib (Tabrecta) - To treat patients with non small cell lung cancer Drug Approval Package: TABRECTA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TABRECTA Company: Novartis Pharmaceuticals Corporation Application Number: 213591 Approval Date: 05/06/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package